Gemma Crupi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gemma Crupi has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Antonino Alex Cartalemi
Functional Genomics of Cancer Unit, Comprehensive Cancer Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
2 shared publications - Davide Cittaro
Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy
2 shared publications - Giovanni Tonon
Vita-Salute San Raffaele University, Milan, Italy
2 shared publications - Guido Gatti
Functional Genomics of Cancer Unit, Comprehensive Cancer Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
2 shared publications - Oronza Antonietta Botrugno
Vita-Salute San Raffaele University, Milan, Italy
2 shared publications Alessio Lupi
Functional Genomics of Cancer Unit, Comprehensive Cancer Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
1 shared publication
Latest Publications
- Open Access
- 4 May 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
The histone methyltransferase NSD3 oncogene triggers ribosomal DNA transcription, interfering with FOSL2 in cancer
Ribosome biogenesis is pervasively enhanced in cancer, and yet, how the expression of ribosomal RNA genes is triggered remains largely unknown. We found that the long isoform of the histone methyltransferase NSD3, NSD3L, one of the most frequently amplified genes in cancer, reshapes the chromatin environment surrounding ribosomal DNA (rDNA), thus triggering rRNA expression. An unbiased mass-spec approach revealed that NSD3L binds several nucleolar proteins and localizes to the nucleolus. NSD3L is essential for the binding of Polymerase I as well as of its activator UBTF (Upstream Binding Transcription Factor) to the entire rDNA locus. Conversely, NSD3L binds to a narrow sequence on rDNA located upstream of the rRNA transcription start site (TSS), displacing FOSL2, a member of the FOS/JUN transcription factor family. Upon NSD3L ablation, FOSL2 increases its binding to this region, leading to reduced rDNA expression. These results suggest a surprising, repressive role for FOSL2 on ribosomal gene expression. We also determined that NSD3L competes with another suppressor of rDNA expression, the histone methyltransferase SUV4-20H, thus impeding the deposition of the repressive histone mark H4K20me3 on rDNA. Therefore, NSD3L balances and counteracts the activities of FOSL2 and SUV4-20H on rDNA, unleashing rDNA synthesis. Accordingly, NSD3L overexpression is associated with enhanced expression of nucleolar genes in several tumor types. We hence propose NSD3L as a central epigenetic orchestrator of rRNA transcription in cancer and an enticing therapeutic target for the large group of cancers presenting with NSD3 amplifications and overexpression.
- 4 May 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessThe histone methyltransferase NSD3 oncogene triggers ribosomal DNA transcription, interfering with FOSL2 in cancer
Ribosome biogenesis is pervasively enhanced in cancer, and yet, how the expression of ribosomal RNA genes is triggered remains largely unknown. We found that the long isoform of the histone methyltransferase NSD3, NSD3L, one of the most frequently amplified genes in cancer, reshapes the chromatin environment surrounding ribosomal DNA (rDNA), thus triggering rRNA expression. An unbiased mass-spec approach revealed that NSD3L binds several nucleolar proteins and localizes to the nucleolus. NSD3L is essential for the binding of Polymerase I as well as of its activator UBTF (Upstream Binding Transcription Factor) to the entire rDNA locus. Conversely, NSD3L binds to a narrow sequence on rDNA located upstream of the rRNA transcription start site (TSS), displacing FOSL2, a member of the FOS/JUN transcription factor family. Upon NSD3L ablation, FOSL2 increases its binding to this region, leading to reduced rDNA expression. These results suggest a surprising, repressive role for FOSL2 on ribosomal gene expression. We also determined that NSD3L competes with another suppressor of rDNA expression, the histone methyltransferase SUV4-20H, thus impeding the deposition of the repressive histone mark H4K20me3 on rDNA. Therefore, NSD3L balances and counteracts the activities of FOSL2 and SUV4-20H on rDNA, unleashing rDNA synthesis. Accordingly, NSD3L overexpression is associated with enhanced expression of nucleolar genes in several tumor types. We hence propose NSD3L as a central epigenetic orchestrator of rRNA transcription in cancer and an enticing therapeutic target for the large group of cancers presenting with NSD3 amplifications and overexpression.
- Open Access
- 3 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Early tolerance and late persistence as alternative drug responses in cancer
Bacteria withstand antibiotic treatment through three alternative mechanisms: resistance, persistence or tolerance. While resistance and persistence have been described, whether drug-induced tolerance exists in cancer cells remains largely unknown. Here, we show that human cancer cells elicit a tolerant response when exposed to commonly used chemotherapy regimens, propelled by the pervasive activation of autophagy, leading to the comprehensive activation of DNA damage repair pathways. After prolonged drug exposure, such tolerant responses morph into persistence, whereby the increased DNA damage repair is entirely reversed. The central regulator of mitophagy PINK1 drives this reduction in DNA repair via the cytoplasmic relocalization of the cell identity master HNF4A, thus hampering HNF4A transcriptional activation of DNA repair genes. We conclude that exposing cancer cells to relevant standard-of-care antitumour therapies induces a pervasive drug-induced tolerant response that might be broadly exploited to increase the impact of first-line, adjuvant treatments and debulking in advanced cancers.
- 3 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Open AccessEarly tolerance and late persistence as alternative drug responses in cancer
Bacteria withstand antibiotic treatment through three alternative mechanisms: resistance, persistence or tolerance. While resistance and persistence have been described, whether drug-induced tolerance exists in cancer cells remains largely unknown. Here, we show that human cancer cells elicit a tolerant response when exposed to commonly used chemotherapy regimens, propelled by the pervasive activation of autophagy, leading to the comprehensive activation of DNA damage repair pathways. After prolonged drug exposure, such tolerant responses morph into persistence, whereby the increased DNA damage repair is entirely reversed. The central regulator of mitophagy PINK1 drives this reduction in DNA repair via the cytoplasmic relocalization of the cell identity master HNF4A, thus hampering HNF4A transcriptional activation of DNA repair genes. We conclude that exposing cancer cells to relevant standard-of-care antitumour therapies induces a pervasive drug-induced tolerant response that might be broadly exploited to increase the impact of first-line, adjuvant treatments and debulking in advanced cancers.